Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization
Background. Despite being more aggressive than other types of breast cancer, there is no suitable treatment for triple-negative breast cancer (TNBC). Here, we designed doxorubicin-containing solid lipid nanoparticles (SLNs) decorated with anti-EGFR/CD44 dual-RNA aptamers, which are overexpressed in...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2022-07, Vol.2022 (1), p.6253978-6253978 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6253978 |
|---|---|
| container_issue | 1 |
| container_start_page | 6253978 |
| container_title | BioMed research international |
| container_volume | 2022 |
| creator | Darabi, Farnosh Saidijam, Massoud Nouri, Fatemeh Mahjub, Reza Soleimani, Meysam |
| description | Background. Despite being more aggressive than other types of breast cancer, there is no suitable treatment for triple-negative breast cancer (TNBC). Here, we designed doxorubicin-containing solid lipid nanoparticles (SLNs) decorated with anti-EGFR/CD44 dual-RNA aptamers, which are overexpressed in TNBC. For more efficiency in the nuclear delivery of doxorubicin, dexamethasone (Dexa) was chemically attached to the surface of nanoparticles. Methods. To prepare the cationic SLNs, 6-lauroxyhexyl BOC-ornithine (LHON) was synthesized and was chemically attached to dexamethasone to form Dexa-LHON complexes. The doxorubicin-containing SLNs were prepared via double emulsification (w/o/w) and the solvent evaporation technique. The preparation of SLNs was statistically optimized using the central composite response surface methodology. Independent factors were the GMS/lecithin concentration ratio and the amount of Tween 80, while responses considered were particle size, polydispersity index, and entrapment efficiency of the nanoparticles. The optimized nanoparticles were studied morphologically using transmission electron microscopy, and in vitro release of doxorubicin from nanoparticles was studied in phosphate-buffered saline. Then, the designated aptamers were attached to the surface of nanoparticles using electrostatic interactions, and their cytotoxicity was assessed in vitro. Results. The size, PDI, zeta potential, EE%, and LE% of the prepared nanoparticles were 101±12.6 nm, 0.341±0.005, +13.6±1.83 mV, 69.98±7.54%, and 10.2±1.06%, respectively. TEM images revealed spherical nanoparticles with no sign of aggregation. In vitro release study exhibited that 96.1±1.97% of doxorubicin was released within 48 h of incubation. The electrostatic attachment of the designated aptamers to the nanoparticles’ surface was confirmed by reducing the zeta potential to −15.6±2.07 mV. The in vitro experiments revealed that the SLNs/DOX/Dexa/CD44 or EGFR aptamers were substantially more successful than SLNs/DOX/Dexa at inhibiting cell proliferation. Using the MDA-MB-468 cell line, we discovered that SLN/DOX/Dexa/CD44/EGFR aptamers were more effective than other constructs in inhibiting cell proliferation (p |
| doi_str_mv | 10.1155/2022/6253978 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9279089</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A710569439</galeid><sourcerecordid>A710569439</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-32d97018d62d71a77f1a5391f81418798a5839147400335bf2bf331d45e3f7b93</originalsourceid><addsrcrecordid>eNp9ks9u1DAQxiMEolXpjQewxAWJpvXf2OGAtGTbUmnVIrpwtbyJs-vKawfbKbQvyGvhaFdFcMAHe6z5-fvGoymK1wieIsTYGYYYn1WYkZqLZ8UhJoiWFaLo-VNMyEFxHOMdzEugCtbVy-KAMEFZTehh8WvmkimbOaVAuQ6cX158AfNR2XKpwlon3YFbb00HFmbI-7VyflAhmdbqCHofwFxbc6_DA_A9mPufPowr0xoHkgfLYAary2u9Vikz4GPQKibQKNfqABptbVZ1-j34HHQWzZB3J-A25SBmB2XBzZDM1jzuM1N9Vw58Myl40GzyizbpsE-_Kl70ykZ9vD-Piq8X58vmU7m4ubxqZouyJYKkkuCu5hCJrsIdR4rzHqncPNSL3DTBa6GYyFfKKYSEsFWPVz0hqKNMk56vanJUfNjpDuNqq7tWuxSUlUMwWxUepFdG_p1xZiPX_l7WmNdQTAJv9wLBfx91THJrYpuboZz2Y5S4yvasopBl9M0_6J0fg8vfmygocF1x9IdaK6ulcb3Pvu0kKmccQVbVlEy2JzuqDT7GoPunkhGU0yjJaZTkfpQy_m6Hb4zr1A_zf_o3wCnGcQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2690829671</pqid></control><display><type>article</type><title>Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization</title><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Darabi, Farnosh ; Saidijam, Massoud ; Nouri, Fatemeh ; Mahjub, Reza ; Soleimani, Meysam</creator><contributor>Ahad, Abdul</contributor><creatorcontrib>Darabi, Farnosh ; Saidijam, Massoud ; Nouri, Fatemeh ; Mahjub, Reza ; Soleimani, Meysam ; Ahad, Abdul</creatorcontrib><description>Background. Despite being more aggressive than other types of breast cancer, there is no suitable treatment for triple-negative breast cancer (TNBC). Here, we designed doxorubicin-containing solid lipid nanoparticles (SLNs) decorated with anti-EGFR/CD44 dual-RNA aptamers, which are overexpressed in TNBC. For more efficiency in the nuclear delivery of doxorubicin, dexamethasone (Dexa) was chemically attached to the surface of nanoparticles. Methods. To prepare the cationic SLNs, 6-lauroxyhexyl BOC-ornithine (LHON) was synthesized and was chemically attached to dexamethasone to form Dexa-LHON complexes. The doxorubicin-containing SLNs were prepared via double emulsification (w/o/w) and the solvent evaporation technique. The preparation of SLNs was statistically optimized using the central composite response surface methodology. Independent factors were the GMS/lecithin concentration ratio and the amount of Tween 80, while responses considered were particle size, polydispersity index, and entrapment efficiency of the nanoparticles. The optimized nanoparticles were studied morphologically using transmission electron microscopy, and in vitro release of doxorubicin from nanoparticles was studied in phosphate-buffered saline. Then, the designated aptamers were attached to the surface of nanoparticles using electrostatic interactions, and their cytotoxicity was assessed in vitro. Results. The size, PDI, zeta potential, EE%, and LE% of the prepared nanoparticles were 101±12.6 nm, 0.341±0.005, +13.6±1.83 mV, 69.98±7.54%, and 10.2±1.06%, respectively. TEM images revealed spherical nanoparticles with no sign of aggregation. In vitro release study exhibited that 96.1±1.97% of doxorubicin was released within 48 h of incubation. The electrostatic attachment of the designated aptamers to the nanoparticles’ surface was confirmed by reducing the zeta potential to −15.6±2.07 mV. The in vitro experiments revealed that the SLNs/DOX/Dexa/CD44 or EGFR aptamers were substantially more successful than SLNs/DOX/Dexa at inhibiting cell proliferation. Using the MDA-MB-468 cell line, we discovered that SLN/DOX/Dexa/CD44/EGFR aptamers were more effective than other constructs in inhibiting cell proliferation (p<0.001). The reduction of cell viability using this construct suggests that targeting numerous proliferation pathways is effective. Conclusion. Overall, the finding of this investigation suggested that SLNs/DOX/Dexa/CD44/EGFR could be a promising new enhanced anticancer delivery system and deserved further preclinical consideration.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2022/6253978</identifier><identifier>PMID: 35845934</identifier><language>eng</language><publisher>New York: Hindawi</publisher><subject>Acids ; Aptamers ; Biomedical research ; Breast cancer ; Cancer therapies ; CD44 antigen ; Cell proliferation ; Cell viability ; Chemical properties ; Chemotherapy ; Chromatography ; Cytotoxicity ; Dexamethasone ; Dosage and administration ; Doxorubicin ; Drug delivery systems ; Drugs ; Dual energy X-ray absorptiometry ; Efficiency ; Electrostatic properties ; Emulsification ; Entrapment ; Epidermal growth factor receptors ; Evaporation ; Glycerol ; Health aspects ; Homogenization ; Incubation ; Lecithin ; Lipids ; Membrane proteins ; Metastasis ; Nanoparticles ; Optimization ; Ornithine ; Pharmaceutical research ; Pharmaceuticals ; Polydispersity ; Production processes ; Response surface methodology ; Stem cells ; Toxicity ; Transmission electron microscopy ; Vehicles ; Zeta potential</subject><ispartof>BioMed research international, 2022-07, Vol.2022 (1), p.6253978-6253978</ispartof><rights>Copyright © 2022 Farnosh Darabi et al.</rights><rights>COPYRIGHT 2022 John Wiley & Sons, Inc.</rights><rights>Copyright © 2022 Farnosh Darabi et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Farnosh Darabi et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-32d97018d62d71a77f1a5391f81418798a5839147400335bf2bf331d45e3f7b93</citedby><cites>FETCH-LOGICAL-c383t-32d97018d62d71a77f1a5391f81418798a5839147400335bf2bf331d45e3f7b93</cites><orcidid>0000-0002-7056-2020 ; 0000-0001-8910-556X ; 0000-0002-5315-8923 ; 0000-0003-2505-8834 ; 0000-0002-7360-6850</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279089/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279089/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><contributor>Ahad, Abdul</contributor><creatorcontrib>Darabi, Farnosh</creatorcontrib><creatorcontrib>Saidijam, Massoud</creatorcontrib><creatorcontrib>Nouri, Fatemeh</creatorcontrib><creatorcontrib>Mahjub, Reza</creatorcontrib><creatorcontrib>Soleimani, Meysam</creatorcontrib><title>Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization</title><title>BioMed research international</title><description>Background. Despite being more aggressive than other types of breast cancer, there is no suitable treatment for triple-negative breast cancer (TNBC). Here, we designed doxorubicin-containing solid lipid nanoparticles (SLNs) decorated with anti-EGFR/CD44 dual-RNA aptamers, which are overexpressed in TNBC. For more efficiency in the nuclear delivery of doxorubicin, dexamethasone (Dexa) was chemically attached to the surface of nanoparticles. Methods. To prepare the cationic SLNs, 6-lauroxyhexyl BOC-ornithine (LHON) was synthesized and was chemically attached to dexamethasone to form Dexa-LHON complexes. The doxorubicin-containing SLNs were prepared via double emulsification (w/o/w) and the solvent evaporation technique. The preparation of SLNs was statistically optimized using the central composite response surface methodology. Independent factors were the GMS/lecithin concentration ratio and the amount of Tween 80, while responses considered were particle size, polydispersity index, and entrapment efficiency of the nanoparticles. The optimized nanoparticles were studied morphologically using transmission electron microscopy, and in vitro release of doxorubicin from nanoparticles was studied in phosphate-buffered saline. Then, the designated aptamers were attached to the surface of nanoparticles using electrostatic interactions, and their cytotoxicity was assessed in vitro. Results. The size, PDI, zeta potential, EE%, and LE% of the prepared nanoparticles were 101±12.6 nm, 0.341±0.005, +13.6±1.83 mV, 69.98±7.54%, and 10.2±1.06%, respectively. TEM images revealed spherical nanoparticles with no sign of aggregation. In vitro release study exhibited that 96.1±1.97% of doxorubicin was released within 48 h of incubation. The electrostatic attachment of the designated aptamers to the nanoparticles’ surface was confirmed by reducing the zeta potential to −15.6±2.07 mV. The in vitro experiments revealed that the SLNs/DOX/Dexa/CD44 or EGFR aptamers were substantially more successful than SLNs/DOX/Dexa at inhibiting cell proliferation. Using the MDA-MB-468 cell line, we discovered that SLN/DOX/Dexa/CD44/EGFR aptamers were more effective than other constructs in inhibiting cell proliferation (p<0.001). The reduction of cell viability using this construct suggests that targeting numerous proliferation pathways is effective. Conclusion. Overall, the finding of this investigation suggested that SLNs/DOX/Dexa/CD44/EGFR could be a promising new enhanced anticancer delivery system and deserved further preclinical consideration.</description><subject>Acids</subject><subject>Aptamers</subject><subject>Biomedical research</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>CD44 antigen</subject><subject>Cell proliferation</subject><subject>Cell viability</subject><subject>Chemical properties</subject><subject>Chemotherapy</subject><subject>Chromatography</subject><subject>Cytotoxicity</subject><subject>Dexamethasone</subject><subject>Dosage and administration</subject><subject>Doxorubicin</subject><subject>Drug delivery systems</subject><subject>Drugs</subject><subject>Dual energy X-ray absorptiometry</subject><subject>Efficiency</subject><subject>Electrostatic properties</subject><subject>Emulsification</subject><subject>Entrapment</subject><subject>Epidermal growth factor receptors</subject><subject>Evaporation</subject><subject>Glycerol</subject><subject>Health aspects</subject><subject>Homogenization</subject><subject>Incubation</subject><subject>Lecithin</subject><subject>Lipids</subject><subject>Membrane proteins</subject><subject>Metastasis</subject><subject>Nanoparticles</subject><subject>Optimization</subject><subject>Ornithine</subject><subject>Pharmaceutical research</subject><subject>Pharmaceuticals</subject><subject>Polydispersity</subject><subject>Production processes</subject><subject>Response surface methodology</subject><subject>Stem cells</subject><subject>Toxicity</subject><subject>Transmission electron microscopy</subject><subject>Vehicles</subject><subject>Zeta potential</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>BENPR</sourceid><recordid>eNp9ks9u1DAQxiMEolXpjQewxAWJpvXf2OGAtGTbUmnVIrpwtbyJs-vKawfbKbQvyGvhaFdFcMAHe6z5-fvGoymK1wieIsTYGYYYn1WYkZqLZ8UhJoiWFaLo-VNMyEFxHOMdzEugCtbVy-KAMEFZTehh8WvmkimbOaVAuQ6cX158AfNR2XKpwlon3YFbb00HFmbI-7VyflAhmdbqCHofwFxbc6_DA_A9mPufPowr0xoHkgfLYAary2u9Vikz4GPQKibQKNfqABptbVZ1-j34HHQWzZB3J-A25SBmB2XBzZDM1jzuM1N9Vw58Myl40GzyizbpsE-_Kl70ykZ9vD-Piq8X58vmU7m4ubxqZouyJYKkkuCu5hCJrsIdR4rzHqncPNSL3DTBa6GYyFfKKYSEsFWPVz0hqKNMk56vanJUfNjpDuNqq7tWuxSUlUMwWxUepFdG_p1xZiPX_l7WmNdQTAJv9wLBfx91THJrYpuboZz2Y5S4yvasopBl9M0_6J0fg8vfmygocF1x9IdaK6ulcb3Pvu0kKmccQVbVlEy2JzuqDT7GoPunkhGU0yjJaZTkfpQy_m6Hb4zr1A_zf_o3wCnGcQ</recordid><startdate>20220706</startdate><enddate>20220706</enddate><creator>Darabi, Farnosh</creator><creator>Saidijam, Massoud</creator><creator>Nouri, Fatemeh</creator><creator>Mahjub, Reza</creator><creator>Soleimani, Meysam</creator><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7056-2020</orcidid><orcidid>https://orcid.org/0000-0001-8910-556X</orcidid><orcidid>https://orcid.org/0000-0002-5315-8923</orcidid><orcidid>https://orcid.org/0000-0003-2505-8834</orcidid><orcidid>https://orcid.org/0000-0002-7360-6850</orcidid></search><sort><creationdate>20220706</creationdate><title>Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization</title><author>Darabi, Farnosh ; Saidijam, Massoud ; Nouri, Fatemeh ; Mahjub, Reza ; Soleimani, Meysam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-32d97018d62d71a77f1a5391f81418798a5839147400335bf2bf331d45e3f7b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acids</topic><topic>Aptamers</topic><topic>Biomedical research</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>CD44 antigen</topic><topic>Cell proliferation</topic><topic>Cell viability</topic><topic>Chemical properties</topic><topic>Chemotherapy</topic><topic>Chromatography</topic><topic>Cytotoxicity</topic><topic>Dexamethasone</topic><topic>Dosage and administration</topic><topic>Doxorubicin</topic><topic>Drug delivery systems</topic><topic>Drugs</topic><topic>Dual energy X-ray absorptiometry</topic><topic>Efficiency</topic><topic>Electrostatic properties</topic><topic>Emulsification</topic><topic>Entrapment</topic><topic>Epidermal growth factor receptors</topic><topic>Evaporation</topic><topic>Glycerol</topic><topic>Health aspects</topic><topic>Homogenization</topic><topic>Incubation</topic><topic>Lecithin</topic><topic>Lipids</topic><topic>Membrane proteins</topic><topic>Metastasis</topic><topic>Nanoparticles</topic><topic>Optimization</topic><topic>Ornithine</topic><topic>Pharmaceutical research</topic><topic>Pharmaceuticals</topic><topic>Polydispersity</topic><topic>Production processes</topic><topic>Response surface methodology</topic><topic>Stem cells</topic><topic>Toxicity</topic><topic>Transmission electron microscopy</topic><topic>Vehicles</topic><topic>Zeta potential</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Darabi, Farnosh</creatorcontrib><creatorcontrib>Saidijam, Massoud</creatorcontrib><creatorcontrib>Nouri, Fatemeh</creatorcontrib><creatorcontrib>Mahjub, Reza</creatorcontrib><creatorcontrib>Soleimani, Meysam</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Darabi, Farnosh</au><au>Saidijam, Massoud</au><au>Nouri, Fatemeh</au><au>Mahjub, Reza</au><au>Soleimani, Meysam</au><au>Ahad, Abdul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization</atitle><jtitle>BioMed research international</jtitle><date>2022-07-06</date><risdate>2022</risdate><volume>2022</volume><issue>1</issue><spage>6253978</spage><epage>6253978</epage><pages>6253978-6253978</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Background. Despite being more aggressive than other types of breast cancer, there is no suitable treatment for triple-negative breast cancer (TNBC). Here, we designed doxorubicin-containing solid lipid nanoparticles (SLNs) decorated with anti-EGFR/CD44 dual-RNA aptamers, which are overexpressed in TNBC. For more efficiency in the nuclear delivery of doxorubicin, dexamethasone (Dexa) was chemically attached to the surface of nanoparticles. Methods. To prepare the cationic SLNs, 6-lauroxyhexyl BOC-ornithine (LHON) was synthesized and was chemically attached to dexamethasone to form Dexa-LHON complexes. The doxorubicin-containing SLNs were prepared via double emulsification (w/o/w) and the solvent evaporation technique. The preparation of SLNs was statistically optimized using the central composite response surface methodology. Independent factors were the GMS/lecithin concentration ratio and the amount of Tween 80, while responses considered were particle size, polydispersity index, and entrapment efficiency of the nanoparticles. The optimized nanoparticles were studied morphologically using transmission electron microscopy, and in vitro release of doxorubicin from nanoparticles was studied in phosphate-buffered saline. Then, the designated aptamers were attached to the surface of nanoparticles using electrostatic interactions, and their cytotoxicity was assessed in vitro. Results. The size, PDI, zeta potential, EE%, and LE% of the prepared nanoparticles were 101±12.6 nm, 0.341±0.005, +13.6±1.83 mV, 69.98±7.54%, and 10.2±1.06%, respectively. TEM images revealed spherical nanoparticles with no sign of aggregation. In vitro release study exhibited that 96.1±1.97% of doxorubicin was released within 48 h of incubation. The electrostatic attachment of the designated aptamers to the nanoparticles’ surface was confirmed by reducing the zeta potential to −15.6±2.07 mV. The in vitro experiments revealed that the SLNs/DOX/Dexa/CD44 or EGFR aptamers were substantially more successful than SLNs/DOX/Dexa at inhibiting cell proliferation. Using the MDA-MB-468 cell line, we discovered that SLN/DOX/Dexa/CD44/EGFR aptamers were more effective than other constructs in inhibiting cell proliferation (p<0.001). The reduction of cell viability using this construct suggests that targeting numerous proliferation pathways is effective. Conclusion. Overall, the finding of this investigation suggested that SLNs/DOX/Dexa/CD44/EGFR could be a promising new enhanced anticancer delivery system and deserved further preclinical consideration.</abstract><cop>New York</cop><pub>Hindawi</pub><pmid>35845934</pmid><doi>10.1155/2022/6253978</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7056-2020</orcidid><orcidid>https://orcid.org/0000-0001-8910-556X</orcidid><orcidid>https://orcid.org/0000-0002-5315-8923</orcidid><orcidid>https://orcid.org/0000-0003-2505-8834</orcidid><orcidid>https://orcid.org/0000-0002-7360-6850</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2022-07, Vol.2022 (1), p.6253978-6253978 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9279089 |
| source | Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Acids Aptamers Biomedical research Breast cancer Cancer therapies CD44 antigen Cell proliferation Cell viability Chemical properties Chemotherapy Chromatography Cytotoxicity Dexamethasone Dosage and administration Doxorubicin Drug delivery systems Drugs Dual energy X-ray absorptiometry Efficiency Electrostatic properties Emulsification Entrapment Epidermal growth factor receptors Evaporation Glycerol Health aspects Homogenization Incubation Lecithin Lipids Membrane proteins Metastasis Nanoparticles Optimization Ornithine Pharmaceutical research Pharmaceuticals Polydispersity Production processes Response surface methodology Stem cells Toxicity Transmission electron microscopy Vehicles Zeta potential |
| title | Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T13%3A14%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-CD44%20and%20EGFR%20Dual-Targeted%20Solid%20Lipid%20Nanoparticles%20for%20Delivery%20of%20Doxorubicin%20to%20Triple-Negative%20Breast%20Cancer%20Cell%20Line:%20Preparation,%20Statistical%20Optimization,%20and%20In%20Vitro%20Characterization&rft.jtitle=BioMed%20research%20international&rft.au=Darabi,%20Farnosh&rft.date=2022-07-06&rft.volume=2022&rft.issue=1&rft.spage=6253978&rft.epage=6253978&rft.pages=6253978-6253978&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2022/6253978&rft_dat=%3Cgale_pubme%3EA710569439%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2690829671&rft_id=info:pmid/35845934&rft_galeid=A710569439&rfr_iscdi=true |